Cormorant Asset Management, LP
Q3 2026 13F-HR Holdings
Net value change ($000)
-462,147
(-23.7%)
New positions
13
Sold out positions
3
Turnover %
21.6%
Sector allocation + QoQ delta (equities-only)
Holdings aggregated across other managers listed in the original SEC filing. View detailed breakdown
Snapshot: Change Analysis
Compared to Q2 2026
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| BLOSSOMHILL THERAPEUTICS INC | 67,366 | NEW |
| ELECTRA THERAPEUTICS INC | 37,862 | NEW |
| ATTOVIA THERAPEUTICS INC | 30,660 | NEW |
| LATIGO BIOTHERAPEUTICS INC | 30,323 | NEW |
| IRD | 26,620 | NEW |
| SNSE | 22,924 | 299.4% |
| PARABILIS MEDICINES INC | 22,709 | 18.0% |
| FREENOME INC | 22,539 | NEW |
| ADARX PHARMACEUTICALS INC | 19,200 | NEW |
| ANL | 17,902 | 39.1% |
Instrument mix + QoQ Δ (ex-options)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|